Actively Recruiting
Albumin and Prognosis of Severely Patients Burns
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-01-15
200
Participants Needed
1
Research Sites
226 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hemodynamic management has long been identified as a key factor affecting burn prognosis. However, large amounts of crystalloid infusion have been associated with the development or aggravation of organ failure (acute respiratory distress syndrome, vascular injury, acute renal failure, and intra-abdominal hypertension) which worsens the final prognosis. The use of albumin during the first 24 hours of burn resuscitation is controversial since capillary leakage may cause transcapillary passage of large molecules into the interstitial space. In fact, human albumin has multiple physiological effects, including regulation of colloidal osmotic pressure, antioxidant properties, nitric oxide modulation and buffering capacities, plasma binding and transport of various substances, which may be particularly important in severe burns. Currently available data suggest that administration of exogenous albumin during the first 24 hours of resuscitation of severe burn patients may be associated with improved outcomes. Multi-centre randomized controlled trials with adequate power should be undertaken in burned patients.
CONDITIONS
Official Title
Albumin and Prognosis of Severely Patients Burns
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients over 18 years of age
- Burns greater than 30% of total body surface area
- Patients admitted to the intensive care unit within 12 hours of a burn injury
You will not qualify if you...
- Pregnancy
- Patients with a limitation of active therapeutics on admission to Burn Intensive Care Unit
- Pre-hospital cardiac arrest
- Moribund patients including those with cardiac arrest before hospital or burns over 95%
- Age over 80 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hopital saint Louis
Paris, France, France, 75010
Actively Recruiting
Research Team
F
François Dr DEPRET, MD
CONTACT
M
Matthieu Pr LEGRAND, MD-PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here